SNDX News and Press, Syndax Pharmaceuticals Inc. From 05/25/21

Canopy set for growth on Canadian economy re-openingWhile not expecting a significant Q4 2021 beat for Canopy Growth (CGC) on June 1, MKM expects a turnaround as the Canadian economy starts to re-open.As a result, the firm is upgrading shares from neutral to buy with a C$55 price target.That ...

Syndax Pharmaceuticals (SNDX) stock price fell 31% to $13.42 on April 20th, 2021 after reporting interim Phase 1 data on its genetically defined leukemia asset SNDX-5613. Investors seemed disappointed in the number of complete responses, some potential safety issues, and the specter o...

Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit PR Newswire WALTHAM, Mass. , May 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical compa...

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2021 Results Earnings Conference Call May 11, 2021, 04:30 PM ET Company Participants Melissa Forst - Argot Partners Dr. Briggs Morrison - Chief Executive Officer Daphne Karydas - Chief Financial Officer Michael Metzger - President, Chief Operating Office...

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Syndax Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

Announcing its Q1 2021 financials, Syndax Pharmaceuticals (SNDX) updated the results of the company’s Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with MLLr and NPM1c mutant relapsed/refractory (R/R) acute leukemias.The new data indicate that the two prior responders of th...

Syndax Pharmaceuticals (SNDX): Q1 GAAP EPS of -$0.54 beats by $0.13.Revenue of $0.38M (flat Y/Y) beats by $0.15M.For the second quarter of 2021, research and development expenses are expected to be $30 to $35 million, and total operating expenses are expected to be $35 to $40 million. For the...

Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update - Today announced two of the prior responders from ongoing Phase 1 portion of AUGMENT-101 trial of SNDX-5613 achieved full count recovery bringing CR/CRh rate up to 23% ...

Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021 PR Newswire WALTHAM, Mass. , May 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical st...

Insider buying decreased significantly last week. Notable Insider Buys: The Greenbrier Companies, Inc., GEE Group, Inc., Landec Corporation, Syndax Pharmaceuticals, Inc., and Bank of Marin Bancorp. Notable Insider Sells: Coinbase Global, Inc., Facebook, Inc., The Charles Schwab Co...